CTRI/2020/05/025167招募中2 期
Evaluation of Efficacy and Safety of Thymoquinone compared to Best supportive care in Patients with COVID-19.
试验速览
- 阶段
- 2 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Ability to provide signed and dated informed consent.
- •2. Male or female aged >= 18 and <=65 years of age.
- •3. Patients who meets the following criteria: a. With confirmed COVID-19 infection as defined below
- •i. Has laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcription- polymerase chain reaction (RT-PCR) or other commercial or public health assay in any specimen, collected <72 hours prior to enrollment; AND
- •ii. Asymptomatic patients without any signs or symptoms as defined in clinical management guidelines for COVID-19 infection issued by the Ministry of Health and Family Welfare (MOHFW); OR Mild (uncomplicated) illness of any duration not requiring hospitalization, and without extreme shortness of breath or severe prostration meeting following criteria:
- •1. Mild symptoms, such as fever, rhinorrhea, mild cough, sore throat, malaise, headache, muscle pain, or malaise, but with no shortness of breath AND
- •2. No signs of any serious lower airway disease as defined in clinical management guidelines for COVID-19 infection issued by MOHFW AND
- •3. RR <20, HR <90, oxygen saturation (pulse oximetry) >93% on room air at screening.
排除标准
- •1. Severe COVID-19 including but not limited to:
- •a. respiratory failure (defined by endotracheal intubation and mechanical ventilation, noninvasive positive pressure ventilation, or clinical diagnosis of respiratory failure in setting of resource limitations)
- •b. Multiple organ dysfunction/failure
- •c. Systolic BP <90 mmHg or Diastolic BP < 60 mm Hg and/or requirement for vasopressor treatment and/or inotropic or mechanical circulatory support
- •2. Confirmed or suspected diagnosis of Acute Respiratory Distress Syndrome (ARDS) at screening
- •3. History of severe chronic respiratory disease and requirement for long-term oxygen therapy
- •4. Expected need for mechanical ventilation within the next 24 hours
- •5. Expected survival of less than 96 hours at the time of presentation
- •6. Receiving renal replacement therapy/dialysis
- •7. Currently receiving or has received in the last 14 days, experimental immune modulators and/or monoclonal antibody therapies
- •8. Current participation in another interventional clinical trial (with an investigational drug) that is not an observational registry
- •9. Confirmed diagnosis of bacterial pneumonia or other active/uncontrolled fungal or viral infections at screening/baseline
- •10. Patients who have received organ transplantation or major surgery in the past 6 months.
- •11. Patients whose ALT/AST levels are 5 times higher than the normal upper limit and total bilirubin is 3 times higher than the upper limit of normal, or Patients with child-Pugh grade C cirrhosis.
- •12. Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the Patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
研究者
相似试验
尚未招募
不适用
Black seed as an oral cleansing agentCTRI/2021/04/033045Saima Yunus Khan
尚未招募
3 期
The effect of thymoquinone on infantile spasmIRCT20200131046317N2Mashhad University of Medical Sciences20
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyEUCTR2020-002100-39-FRPTC THERAPEUTICS, INC.80
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyGenetically determined mitochondrial disease and associated refractory epilepsyMedDRA version: 20.0Level: LLTClassification code 10077953Term: Refractory epilepsySystem Organ Class: 100000004852MedDRA version: 20.0Level: HLTClassification code 10052637Term: Genetic mitochondrial abnormalities NECSystem Organ Class: 100000004850EUCTR2020-002100-39-PLPTC THERAPEUTICS, INC.80
进行中（未招募）
1 期
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyGenetically determined mitochondrial disease and associated refractory epilepsyEUCTR2020-002100-39-SEPTC THERAPEUTICS, INC.88